Dr Pooja Dewan

Honorary Research Fellow (School of Cardiovascular & Metabolic Health)

email: Pooja.Dewan@glasgow.ac.uk

Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF

Import to contacts

https://orcid.org/0000-0003-2927-4075

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020 | 2019

Number of items: 25.

2023

Kondo, T. et al. (2023) Clinical characteristics and outcomes in patients with heart failure: are there thresholds and inflection points in left ventricular ejection fraction and thresholds justifying a clinical classification? Circulation, 148(9), pp. 732-749. (doi: 10.1161/CIRCULATIONAHA.122.063642) (PMID:37366061)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Butt, J. H. et al. (2023) Urinary cGMP (cyclic guanosine monophosphate)/BNP (B-type natriuretic peptide) ratio, sacubitril/valsartan, and outcomes in heart failure with reduced ejection fraction: an analysis of the PARADIGM-HF trial. Circulation: Heart Failure, 16(3), pp. 247-258. (doi: 10.1161/CIRCHEARTFAILURE.122.010111) (PMID:36943907) (PMCID:PMC10022671)

Johansen, N. D. et al. (2023) A composite score summarizing use and dosing of evidence-based medical therapies in heart failure: a nationwide cohort study. Circulation: Heart Failure, 16(2), e009729. (doi: 10.1161/CIRCHEARTFAILURE.122.009729) (PMID:36809039)

2022

Butt, J. H. et al. (2022) Sacubitril/valsartan and frailty in patients with heart failure and preserved ejection fraction. Journal of the American College of Cardiology, 80(12), pp. 1130-1143. (doi: 10.1016/j.jacc.2022.06.037) (PMID:36050227)

Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)

Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)

Yeoh, S. E., Dewan, P. , Serenelli, M., Ferreira, J. P., Pitt, B., Swedberg, K., Veldhuisen, D. J., Zannad, F., Jhund, P. S. and McMurray, J. J.V. (2022) Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. European Journal of Heart Failure, 24(3), pp. 529-538. (doi: 10.1002/ejhf.2350) (PMID:34536265) (PMCID:PMC10654446)

2021

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

2020

Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

Dewan, P. , Jhund, P. S. and McMurray, J. J.V. (2020) VICTORIA in context. European Journal of Heart Failure, 22(10), pp. 1747-1751. (doi: 10.1002/ejhf.1833) (PMID:32363731)

Solomon, S. D. et al. (2020) Effect of dapagliflozin in patients with HFrEF treated with sacubitril/valsartan: the DAPA-HF trial. JACC: Heart Failure, 8(10), pp. 811-818. (doi: 10.1016/j.jchf.2020.04.008) (PMID:32653447)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)

Dewan, P. et al. (2020) Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. European Journal of Heart Failure, 22(7), pp. 1247-1258. (doi: 10.1002/ejhf.1867) (PMID:32539224)

Dewan, P. , Jackson, A., Lam, C. S.P., Pfeffer, M. A., Zannad, F., Pitt, B., Solomon, S. D. and McMurray, J. J.V. (2020) Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure, 22(5), pp. 898-901. (doi: 10.1002/ejhf.1776) (PMID:32115864)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

2019

Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)

Ferreira, J. P., Rossignol, P., Dewan, P. , Lamiral, Z., White, W. B., Pitt, B., McMurray, J. J.V. and Zannad, F. (2019) Income level and inequality as complement to geographical differences in cardiovascular trials. American Heart Journal, 218, pp. 66-74. (doi: 10.1016/j.ahj.2019.08.019) (PMID:31707330)

Rørth, R., Dewan, P. , Kristensen, S. L., Jhund, P. S. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2019) Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 108(8), pp. 868-877. (doi: 10.1007/s00392-019-01415-z) (PMID:30689020) (PMCID:PMC6652172)

Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)

Dewan, P. et al. (2019) Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 21(5), pp. 577-587. (doi: 10.1002/ejhf.1347) (PMID:30536678) (PMCID:PMC6607486)

Dewan, P. et al. (2019) Income inequality and outcomes in heart failure: a global between-country analysis. JACC: Heart Failure, 7(4), pp. 336-346. (doi: 10.1016/j.jchf.2018.11.005) (PMID:30738981)

Dewan, P. et al. (2019) Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology, 73(1), pp. 29-40. (doi: 10.1016/j.jacc.2018.09.081) (PMID:30621948)

This list was generated on Sat Apr 20 00:42:33 2024 BST.

Jump to: Articles